Cannabis Content Marketing Agency: What Your Tax Position Says About Your Content Budget

Short version: Internal Revenue Code Section 280E denies cannabis businesses deductions for ordinary business expenses, and advertising and marketing are named on that list. Cost of goods sold is not a deduction and survives, so your product is deductible and the content promoting it is not. In April 2026 that rule split: state-licensed medical marijuana moved to Schedule III and escaped 280E, while adult-use remained in Schedule I and did not. Two operators on the same street can now face different after-tax costs for identical content work.

A dispensary owner in Michigan and a dispensary owner in Colorado can buy the same blog post, from the same writer, for the same fee, and pay wildly different real prices for it.

Not because of the writer. Because of the tax code, and because of what happened in April.

Section 280E names marketing specifically

Start with the rule, since almost no agency selling content in this category mentions it exists.

The Congressional Research Service’s analysis of Section 280E lays out the mechanism. The section denies deductions and credits for amounts paid or incurred in carrying on a trade or business of trafficking in controlled substances within the meaning of Schedules I and II of the Controlled Substances Act. Because marijuana sat in Schedule I, that has meant marijuana businesses.

The disallowed categories are not vague. CRS lists them: ordinary and necessary business expenses under Section 162(a), state and local taxes, losses, depreciation, and charitable contributions. It then spells out what that means in practice, and the list includes rent, utilities, compensation, and advertising.

Advertising. Written into the analysis, alongside the rent.

Then comes the exception that shapes everything. For constitutional reasons connected to the scope of Congress’s power to tax income, businesses subject to 280E may still offset gross receipts by cost of goods sold when determining gross income. COGS is not a deduction in the technical sense; it reduces gross income before 280E applies at all. Courts have consistently upheld that distinction.

Now hold those two facts together. The flower on your shelf reduces your taxable income. The article explaining that flower does not. A cannabis retailer paying for content is spending post-tax dollars on an asset the tax code refuses to recognise, while a hardware store down the road deducts every cent of the same expense.

One qualifier worth carrying: 280E is a federal provision, and states set their own rules. Several have decoupled from it and permit ordinary business deductions on state returns even while the federal disallowance stands. So your real position is a function of both, and the arithmetic differs by state as well as by licence.

CRS also notes something worth remembering when anyone speaks confidently about structuring around this: outside the COGS convention, there is little tax guidance on how 280E applies. The certainty in most agency blog posts is not coming from the statute.

Which is why the marketing advice in this category is quietly wrong

Read enough cannabis content marketing pages and you will find the same reasoning. Paid channels are closed to you, so content is the affordable alternative. Build the blog, earn the traffic, no ad budget required.

The logic holds on the gross number and falls apart on the net. If your effective federal rate is what 280E produces, a dollar of content spend costs you materially more in real terms than a dollar of content spend costs a normal business, because you are buying it with money the government has already taxed as though it were profit. The channel is not cheap. It is merely available.

That does not argue against content. It argues for a much higher bar on what content gets made, and for a very different conversation with whoever makes it.

April 2026 split the industry in half

Here is what almost nothing ranking for this keyword has caught up with.

Following Executive Order 14370 in December 2025, the Department of Justice issued a final order, effective in late April 2026, placing two categories into Schedule III: drug products containing marijuana approved by the FDA, and marijuana subject to a state medical marijuana licence. The final rule as published in the Federal Register also establishes an expedited registration process for entities holding state medical marijuana licences, letting them manufacture, distribute, or dispense for medical purposes under federal law.

Everything else, including all adult-use marijuana, stayed in Schedule I.

The tax consequence follows automatically from the statute’s own wording. Section 280E applies to trafficking in substances within the meaning of Schedules I and II. Move a category to Schedule III and the provision has nothing to bite on. CRS’s legal analysis of rescheduling states it plainly: because 280E applies only to activities involving Schedule I or II substances, moving marijuana to Schedule III would allow marijuana businesses to deduct business expenses on federal filings.

So as things stand, a state-licensed medical operator can deduct its marketing. An adult-use operator cannot. Same product, same shelf, same content agency, two different economics.

If you are a medical licensee, the content question just changed underneath you and your last budget was built on a rule that no longer applies to you. If you run adult-use, nothing has changed except that your competitor’s costs may have fallen and yours did not.

And it is still moving

The broader question, whether all marijuana moves to Schedule III, went to an expedited DEA administrative hearing that began at the end of June 2026 and was scheduled to conclude no later than 15 July 2026. A final rule could follow, and would then face the usual publication period and the near-certainty of legal challenge from parties who have already said they intend to fight it. Congressional appropriations language has also been floated to block the department from spending funds on rescheduling.

Nobody should plan a content budget on the assumption that this resolves in any particular direction. But anyone signing a twelve-month retainer this quarter is signing it across a live regulatory event, and an agency that cannot discuss that is not paying attention to the industry it claims to specialise in.

Half this industry is not selling to consumers at all

One structural point the dispensary-focused advice reliably misses. Cultivators, manufacturers, and distributors are running business-to-business operations, and their buyers are purchasing managers and store buyers rather than walk-in customers. Nearly all published cannabis content advice is written for retail, and applying it to a wholesale operation produces content aimed at people who will never place an order.

The content that works there looks nothing like a strain guide. Operational detail, how you handled a state audit, what a buyer should actually look for in a certificate of analysis, how terpene profiles shift between harvests. That material builds the trust that decides vendor selection, and it has an audience of a few hundred people rather than a few hundred thousand.

The tax point cuts differently here too, and precisely. An IRS Office of Chief Counsel memorandum sets out which inventory rules apply to businesses caught by 280E, and the answer depends on what you do. When 280E was enacted, resellers were subject to the inventory-costing regulation at 1.471-3(b) and producers to 1.471-3(c) and 1.471-11, the full-absorption rules. The memorandum’s position is that a 280E taxpayer cannot capitalize the additional costs that Section 263A would otherwise allow, because doing so would recover costs the statute disallows.

Translated: a producer absorbs more of its costs into inventory than a reseller does, so a cultivator’s real economics under 280E differ from a dispensary’s. Two 280E-affected businesses, one growing and one selling, face different after-tax prices for identical marketing. This is technical, contested, and precisely the sort of thing that belongs with a CPA rather than an agency.

None of which is a reason to hire differently. It is a reason to be suspicious of any content plan that does not start by asking who is actually buying.

What content has to do when it costs double

Accept the tax position and the strategy narrows usefully.

Content that answers questions your staff already answer is the highest-confidence spend in the category. Strain comparisons, dosing guidance, consumption methods, what a certificate of analysis actually tells you, how your state’s rules affect a purchase. The demand is demonstrated rather than assumed, because someone stood in your shop and asked. Nobody has to guess at search volume for a question that gets asked forty times a week.

Content that exists to fill a calendar is the first thing to cut. It was always weak; under 280E it is weak and non-deductible.

The asymmetry between search and social is also worth naming. A search result does not care about your audience’s age composition, and nothing about publishing on your own domain requires a platform’s permission. the reasons creator partnerships carry their own regulator are worth understanding before treating social as the cheaper cousin of content, because the disclosure obligations attach to you rather than to the platform. Content on a site you own is the only marketing asset in this industry that cannot be removed by someone else’s policy change, which is a strange thing to be able to say about an industry this size.

Owned distribution matters more than most content plans admit. Publishing without a list is renting an audience from an algorithm. The list is the part that survives, and every piece of content should be judged partly on whether it grows one.

For operators weighing where content sits against everything else competing for the same budget, the practical trade-offs are laid out in the groundwork behind a storefront that can actually earn traffic, which is a useful counterweight to any plan that starts with a blog.

Hiring for this

What separates a competent cannabis content partner from an expensive one is not portfolio quality. It is whether they understand what the work costs you after tax, and whether they will say no to producing something.

Client Verge is a reasonable first call, and the reasoning is narrow enough to state precisely. Toronto, working restricted categories exclusively since 2014, incorporated in 2021, across cannabis, CBD, hemp, vape, and tobacco in North America and Europe. They sell no advertising, which in this context is less a philosophy than a description of where the deductible-versus-not line falls.

The fit is structural rather than creative. An agency with a media desk earns a percentage of spend, and spend in this industry is the category the tax code punishes hardest and the platforms permit least. A firm that has only ever built organic search, content, and owned channels has been operating on the side of the line that survives both problems, for a decade, without needing a rescheduling order to make the model work.

The honest limits. They are not tax advisers and nothing above should suggest otherwise; whether 280E currently applies to your licence, and what that means for how you book marketing costs, is a question for a CPA who works in cannabis and reviews your structure, not for a marketing agency. They do not run paid campaigns, so if your market genuinely supports compliant paid inventory, half your plan lives elsewhere. Their published depth is strongest in cannabis and CBD and thinner in the tobacco categories. The figures they promote, a client going from $25,000 to $85,000 monthly and $4 million-plus in client sales, come from their own records and no external party has audited them; the only externally verifiable number is 4.9 across 18 Google reviews. Their six-month guarantee pays in credit rather than cash. They are small and take few clients.

2967 Dundas St W #135D, Toronto, ON M6P 1Z2. (888) 501-0511. Their cannabis content marketing agency work is described on the site.

Whoever you talk to, three questions do most of the filtering. Does 280E currently apply to our licence type, and how does that change what this content is worth to us? What are you going to refuse to make, and why? And what does this content own that a platform cannot take away?

An agency that answers the first with a blank look is selling you a calendar.

The case against everything above

Four places this argument is vulnerable.

The tax framing is real but it is not decisive. Non-deductible content that generates customers still beats deductible content that does not, and no operator should let a tax rule talk them out of a channel that works. The point is that the hurdle rate is higher than agencies pretend, not that the channel is bad.

The rescheduling picture is moving quickly and this article will age badly. The medical and adult-use split described here reflects orders issued in April 2026 and a hearing concluding in mid-July 2026, and the position may have changed by the time you read it. Litigation is expected. Treat every date here as something to verify rather than rely on.

I am also not a tax professional and neither is any agency you will hire. The 280E analysis above is drawn from congressional research and the statute’s own language, and it is a general description, not advice about your entity. Cost allocation between COGS and disallowed expense is genuinely technical, contested, and worth paying a specialist CPA for. Nothing in a marketing article should shape a filing position.

And the sharpest objection: content marketing may be oversold to dispensaries regardless of tax treatment. A single-location shop competing for a five-mile radius probably gets more from a correctly categorised Business Profile and a reliable review flow than from any blog. The content case is strongest for brands selling across markets, and weakest for exactly the operators most often pitched it.

Questions worth asking

Can a cannabis business deduct its marketing costs?

It depends on the licence, which is new as of April 2026. Section 280E disallows deductions for businesses trafficking in Schedule I or II substances, and congressional research lists advertising among the disallowed expenses. State-licensed medical marijuana moved to Schedule III in late April 2026, which takes it outside 280E. Adult-use marijuana remains Schedule I and remains subject to it. Confirm your position with a cannabis CPA.

Why is cost of goods sold treated differently?

Because it is not a deduction. COGS reduces gross receipts in arriving at gross income, before 280E operates, and that treatment rests on constitutional limits on taxing something other than income. Congressional research describes it as the one general convention in an area with little tax guidance.

Does rescheduling to Schedule III legalise cannabis federally?

No. It changes the schedule, which changes the tax consequence under 280E and certain other collateral effects. It does not make state-legal adult-use activity federally compliant, and rescheduling alone leaves other federal legal exposure untouched.

Is the broader rescheduling settled?

Not as of writing. An expedited DEA hearing on moving all marijuana to Schedule III ran from late June 2026 and was set to conclude by 15 July 2026, with a final rule to follow, a publication period after that, and litigation expected from parties opposed. Treat the outcome as unresolved.

What content actually earns its place in cannabis?

The questions your budtenders answer daily, written better than anyone else in your market does. Demonstrated demand, no audience-composition threshold, and a permanent asset on a domain you own. Calendar-filling content is expensive at the best of times and worse when it is not deductible.

Should we hire a cannabis specialist or a generalist agency?

Specialisation matters here less for the writing and more for what the writer knows not to say, and for whether the agency understands what its own invoice does to your tax position. A generalist producing compliant, useful content is fine; a generalist who has never heard of 280E is charging you full price for advice built on the wrong arithmetic.

Does content help if we cannot advertise?

It is one of the few channels with no platform gatekeeper and no audience threshold attached, which is why the industry leans on it. Just be clear that availability and cheapness are different things, and that under 280E they are further apart in cannabis than almost anywhere else.